Acrivon Therapeutics, Inc. ACRV
Set alert
1.61 USD 0.00 0.00%
At close
1.61 0.00 +0.08%
Pre-market · Nov 3, 6:29 AM ET
1.58 Day range 1.71
1.27 52-week range 3.56
- YTD
- -33.20%
- 1 year
- -19.10%
- Open
- 1.66
- Prev close
- 1.61
- Mkt cap
- 68.99M
- Vol
- 228.22K
- Avg vol
- 294.81K
- EPS
- -1.88
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.58
- High
- 1.71
- Forward P/E
- -2.31
- Beta
- 0.00
- Short ratio
- 15.38
- Inst. own
- 75.98%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 7.44
- 200-d avg
- 7.65
- 1y target
- 21.11
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 21.11 +1211.2% upside
Now 1.61
- Target (low)
- 16.00
- Target (mean)
- 21.11
- Target (high)
- 30.00
Ratings (0m) 10 10 buy · 0 hold · 0 sell
- Strong buy5
- Buy5
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 10
- 1 month ago 10
- 2 months ago 10
- 3 months ago 10
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.70286 | -0.81 – -0.61 | -0.87 | +19.2% | 0 | 0.0% | 7 |
| Next quarter | -0.705 | -0.87 – -0.54 | -0.73 | +3.4% | 0 | 0.0% | 2 |
| Current year | -2.63 | -3.08 – -2.45 | -2.74 | +4.1% | 0 | 0.0% | 6 |
| Next year | -2.96 | -3.95 – -2.00 | -2.63 | -12.6% | 809.20K | 0.0% | 7 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 14, 2024 | BMO Capital | Maintained | Outperform | Outperform |
| Nov 14, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 16, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Sep 16, 2024 | Ladenburg Thalmann | Upgrade | Neutral | Buy |
| Sep 16, 2024 | BMO Capital | Reiterated | Outperform | Outperform |
| Sep 16, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 13, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 15, 2024 | BMO Capital | Reiterated | Outperform | Outperform |
| May 14, 2024 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 29, 2024 | Ladenburg Thalmann | Downgrade | Buy | Neutral |
| Apr 26, 2024 | BMO Capital | Maintained | Outperform | Outperform |
| Apr 25, 2024 | JMP Securities | Maintained | Market Outperform | Market Outperform |
| Apr 25, 2024 | Piper Sandler | Maintained | Overweight | Overweight |
| Apr 25, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 5, 2024 | Ladenburg Thalmann | Maintained | Buy | Buy |
| Apr 1, 2024 | BMO Capital | Reiterated | Outperform | Outperform |
| Apr 1, 2024 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Mar 28, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 1, 2024 | JMP Securities | Initiated | — | Market Outperform |
| Nov 10, 2023 | BMO Capital | Maintained | Outperform | Outperform |
| Oct 5, 2023 | Maxim Group | Initiated | — | Buy |
| Sep 6, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 18, 2023 | JonesTrading | Initiated | — | Buy |
| Aug 11, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 2, 2023 | Oppenheimer | Initiated | — | Outperform |
| May 8, 2023 | BMO Capital | Initiated | — | Outperform |
| May 2, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Apr 20, 2023 | HC Wainwright & Co. | Initiated | — | Buy |
| Dec 12, 2022 | Cowen & Co. | Initiated | — | Outperform |
| Dec 12, 2022 | Jefferies | Initiated | — | Buy |